Circulating Hepatocyte Growth Factor Is Correlated with Resistance to Cetuximab in Metastatic Colorectal Cancer

被引：0

作者：

Yonesaka, Kimio ^{[1
]}

Satoh, Taroh ^{[2
]}

Ueda, Shinya ^{[1
]}

Yoshida, Takeshi ^{[1
]}

Takeda, Masayuki ^{[1
]}

Shimizu, Toshio ^{[1
]}

Okamoto, Isamu ^{[3
]}

Nishio, Kazuto ^{[4
]}

Tamura, Takao ^{[1
]}

Nakagawa, Kazuhiko ^{[1
]}

机构：

[1] Kinki Univ, Sch Med, Dept Med Oncol, Osaka, Osaka 5898511, Japan

[2] Osaka Univ, Grad Sch Med, Dept Gastroenterol Surg, Osaka, Japan

[3] Kyushu Univ, Ctr Clin & Translat Res, Fukuoka 812, Japan

[4] Kinki Univ, Sch Med, Genome Biol, Osaka, Osaka 5898511, Japan

来源：

ANTICANCER RESEARCH | 2015年 / 35卷 / 03期

关键词：

Hepatocyte growth factor; amphiregulin; transforming growth factor-alpha; epidermal growth factor receptor; cetuximab; colorectal cancer; FACTOR RECEPTOR; ERBB RECEPTORS; EXPRESSION; GEFITINIB; MUTATION; AMPHIREGULIN; CHEMOTHERAPY; PANITUMUMAB; EPIREGULIN; PROGNOSIS;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background/Aim: The epidermal growth factor family (EGF) has been suggested to influence the sensitivity to anti-epidermal growth factor receptor therapy. We examined the correlation between circulating levels of the epidermal growth factors amphiregulin and transforming growth factor-alpha (TGF-alpha) and the MET ligand hepatocyte growth factor and sensitivity to the anti-epidermal growth factor receptor antibody in colorectal cancer (CRC) patients. Materials and Methods: Plasma levels of each ligand were measured by enzyme-linked immunosorbent assay in 51 patients with wild-type KRAS CRC. Results: Patients with high hepatocyte growth factor (HGF) levels had a significantly lower disease control rate (DCR) and shorter median progression-free survival (PFS) and overall survival (OS) than those with low expression levels. Amphiregulin was correlated with objective response rate (ORR) but not with PFS or OS. Cetuximab response and survival were not associated with TGF-alpha. Conclusion: Circulating HGF may help identify CRC patients most likely to benefit from anti-epidermal growth factor receptor antibody therapy.

引用

页码：1683 / 1689

页数：7

共 27 条

[1] ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics [J].

Arteaga, Carlos L. ;

Engelman, Jeffrey A. .

CANCER CELL, 2014, 25 (03) :282-303

[2] Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer [J].

Bardelli, Alberto ;

Corso, Simona ;

Bertotti, Andrea ;

Hobor, Sebastijan ;

Valtorta, Emanuele ;

Siravegna, Giulia ;

Sartore-Bianchi, Andrea ;

Scala, Elisa ;

Cassingena, Andrea ;

Zecchin, Davide ;

Apicella, Maria ;

Migliardi, Giorgia ;

Galimi, Francesco ;

Lauricella, Calogero ;

Zanon, Carlo ;

Perera, Timothy ;

Veronese, Silvio ;

Corti, Giorgio ;

Amatu, Alessio ;

Gambacorta, Marcello ;

Diaz, Luis A., Jr. ;

Sausen, Mark ;

Velculescu, Victor E. ;

Comoglio, Paolo ;

Trusolino, Livio ;

Di Nicolantonio, Federica ;

Giordano, Silvia ;

Siena, Salvatore .

CANCER DISCOVERY, 2013, 3 (06) :658-673

[3] IDENTIFICATION OF THE HEPATOCYTE GROWTH-FACTOR RECEPTOR AS THE C-MET PROTOONCOGENE PRODUCT [J].

BOTTARO, DP ;

RUBIN, JS ;

FALETTO, DL ;

CHAN, AML ;

KMIECIK, TE ;

VANDEWOUDE, GF ;

AARONSON, SA .

SCIENCE, 1991, 251 (4995) :802-804

[4] Neuregulin expression modulates clinical response to trastuzumab in patients with metastatic breast cancer [J].

de Alava, Enrique ;

Ocana, Alberto ;

Abad, Mar ;

Carlos Montero, Juan ;

Esparis-Ogando, Azucena ;

Rodriguez, Cesar A. ;

Otero, Ana P. ;

Hernandez, Teresa ;

Cruz, Juan J. ;

Pandiella, Atanasio .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (19) :2656-2663

[5] Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study [J].

Douillard, Jean-Yves ;

Siena, Salvatore ;

Cassidy, James ;

Tabernero, Josep ;

Burkes, Ronald ;

Barugel, Mario ;

Humblet, Yves ;

Bodoky, Gyoergy ;

Cunningham, David ;

Jassem, Jacek ;

Rivera, Fernando ;

Kocakova, Ilona ;

Ruff, Paul ;

Blasinska-Morawiec, Maria ;

Smakal, Martin ;

Canon, Jean-Luc ;

Rother, Mark ;

Oliner, Kelly S. ;

Wolf, Michael ;

Gansert, Jennifer .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (31) :4697-4705

[6] ERBB receptors and cancer: The complexity of targeted inhibitors [J].

Hynes, NE ;

Lane, HA .

NATURE REVIEWS CANCER, 2005, 5 (05) :341-354

[7] Amphiregulin and Epiregulin mRNA Expression in Primary Tumors Predicts Outcome in Metastatic Colorectal Cancer Treated With Cetuximab [J].

Jacobs, Bart ;

De Roock, Wendy ;

Piessevaux, Hubert ;

Van Oirbeek, Robin ;

Biesmans, Bart ;

De Schutter, Jef ;

Fieuws, Steffen ;

Vandesompele, Jo ;

Peeters, Marc ;

Van Laethem, Jean-Luc ;

Humblet, Yves ;

Penault-Llorca, Frederique ;

De Hertogh, Gert ;

Laurent-Puig, Pierre ;

Van Cutsem, Eric ;

Tejpar, Sabine .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (30) :5068-5074

[8] Cetuximab for the treatment of colorectal cancer [J].

Jonker, Derek J. ;

O'Callaghan, Chris J. ;

Karapetis, Christos S. ;

Zalcberg, John R. ;

Tu, Dongsheng ;

Au, Heather-Jane ;

Berry, Scott R. ;

Krahn, Marianne ;

Price, Timothy ;

Simes, R. John ;

Tebbutt, Niall C. ;

van Hazel, Guy ;

Wierzbicki, Rafal ;

Langer, Christiane ;

Moore, Malcolm J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (20) :2040-2048

[9] K-ras mutations and benefit from cetuximab in advanced colorectal cancer [J].

Karapetis, Christos S. ;

Khambata-Ford, Shirin ;

Jonker, Derek J. ;

O'Callaghan, Chris J. ;

Tu, Dongsheng ;

Tebbutt, Niall C. ;

Simes, R. John ;

Chalchal, Haji ;

Shapiro, Jeremy D. ;

Robitaille, Sonia ;

Price, Timothy J. ;

Shepherd, Lois ;

Au, Heather-Jane ;

Langer, Christiane ;

Moore, Malcolm J. ;

Zalcberg, John R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (17) :1757-1765

[10] Impact of Serum Hepatocyte Growth Factor on Treatment Response to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non-Small Cell Lung Adenocarcinoma [J].

Kasahara, Kazuo ;

Arao, Tokuzo ;

Sakai, Kazuko ;

Matsumoto, Kazuko ;

Sakai, Asao ;

Kimura, Hideharu ;

Sone, Takashi ;

Horiike, Atsushi ;

Nishio, Makoto ;

Ohira, Tatsuo ;

Ikeda, Norihiko ;

Yamanaka, Takeharu ;

Saijo, Nagahiro ;

Nishio, Kazuto .

CLINICAL CANCER RESEARCH, 2010, 16 (18) :4616-4624

← 1 2 3 →